ARDT Stock Analysis: Ardent Health | NYSE
Medical Care Facilities | NYSE, USA | Market Cap: 1.542m USD | 12M Return: -29.4% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 5.37M
Qual. Beats: 0
Rev. Trend: 98.9%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 1.9 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Ardent Health, Inc. (NYSE: ARDT) is a U.S. healthcare operator that owns and runs a network of hospitals, clinics, and ambulatory facilities delivering both general and specialty services - including internal medicine, general surgery, cardiology, oncology, orthopedics, womens health, neurology, urology, and emergency care. Its footprint spans acute care hospitals, rehabilitation hospitals, surgical hospitals, ambulatory surgery centers, urgent care centers, freestanding emergency departments, diagnostic imaging centers, primary and specialty care clinics, and telehealth services, covering both inpatient and outpatient settings.
The company operates within the Health Care Facilities sub-industry of the broader Health Care sector, a grouping that includes for-profit and non-profit operators of hospitals, outpatient centers, and ancillary care sites. Ardents model reflects a common industry approach of pairing higher-acuity inpatient services (acute and surgical hospitals) with lower-acuity ambulatory and digital channels to broaden patient access and diversify revenue. Founded in 2001 and headquartered in Brentwood, Tennessee, the company is a subsidiary of EGI-AM Investments, L.L.C., and adopted its current corporate name in June 2025 after listing on the NYSE in July 2024.
- Same-hospital admissions growth drives quarterly revenue outperformance
- Rising nursing labor and contract staffing costs pressure operating margins
- Commercial and Medicaid reimbursement rate negotiations impact net patient revenue
| Net Income: 134.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.04 > 0.02 and ΔFCF/TA 1.66 > 1.0 |
| NWC/Revenue: 16.62% < 20% (prev 15.46%; Δ 1.17% < -1%) |
| CFO/TA 0.08 > 3% & CFO 430.9m > Net Income 134.3m |
| Net Debt (2.85b) to EBITDA (505.8m): 5.64 < 3 |
| Current Ratio: 2.12 > 1.5 & < 3 |
| Outstanding Shares: last quarter (141.8m) vs 12m ago 0.76% < -2% |
| Gross Margin: 49.72% > 18% (prev 76.36%; Δ -26.64% > 0.5%) |
| Asset Turnover: 126.5% > 50% (prev 122.7%; Δ 3.84% > 0%) |
| Interest Coverage Ratio: 6.63 > 6 (EBIT TTM 343.3m / Interest Expense TTM 51.8m) |
| A: 0.20 (Total Current Assets 2.02b - Total Current Liabilities 951.5m) / Total Assets 5.25b |
| B: 0.10 (Retained Earnings 541.5m / Total Assets 5.25b) |
| C: 0.07 (EBIT TTM 343.3m / Avg Total Assets 5.08b) |
| D: 0.49 (Book Value of Equity 1.73b / Total Liabilities 3.52b) |
| Altman-Z'' = 2.64 = A |
| DSRI: 0.86 (Receivables 709.2m/776.5m, Revenue 6.43b/6.02b) |
| GMI: 1.54 (GM 76.36% / 49.72%) |
| AQI: 0.94 (AQ_t 0.21 / AQ_t-1 0.22) |
| SGI: 1.07 (Revenue 6.43b / 6.02b) |
| TATA: -0.06 (NI 134.3m - CFO 430.9m) / TA 5.25b) |
| Beneish M = -2.65 (Cap -4..+1) = A |
As of July 11, 2026, the stock is trading at USD 10.08 with a total of 337,766 shares traded. Over the past week, the price has changed by -6.32%, over one month by +8.15%, over three months by +7.23% and over the past year by -29.36%.
Current recommended Stop Loss: 9.40 (which is 6.7% or 1.4 ATR below the current price).
Ardent Health has received a consensus analysts rating of 4.45. Therefore, it is recommended to buy ARDT.
- StrongBuy: 7
- Buy: 2
- Hold: 2
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 12.3 | 22.2% |
P/E Trailing = 11.4468
P/E Forward = 9.2937
P/S = 0.2399
P/B = 1.0863
Revenue TTM = 6.43b USD
EBIT TTM = 343.3m USD
EBITDA TTM = 505.8m USD
Long Term Debt = 1.07b USD (from longTermDebt, last quarter)
Short Term Debt = 37.6m USD (from shortTermDebt, last quarter)
Debt = 3.46b USD (from shortLongTermDebtTotal, last quarter) + Leases 1.18b
Net Debt = 2.85b USD (calculated: Debt 3.46b - CCE 609.7m)
Enterprise Value = 4.39b USD (1.54b + Debt 3.46b - CCE 609.7m)
Interest Coverage Ratio = 6.63 (Ebit TTM 343.3m / Interest Expense TTM 51.8m)
EV/FCF = 20.55x (Enterprise Value 4.39b / FCF TTM 213.8m)
FCF Yield = 4.87% (FCF TTM 213.8m / Enterprise Value 4.39b)
FCF Margin = 3.33% (FCF TTM 213.8m / Revenue TTM 6.43b)
Net Margin = 2.09% (Net Income TTM 134.3m / Revenue TTM 6.43b)
Gross Margin = 49.72% ((Revenue TTM 6.43b - Cost of Revenue TTM 3.23b) / Revenue TTM)
Gross Margin QoQ = 15.36% (prev 42.13%)
Tobins Q-Ratio = 0.84 (Enterprise Value 4.39b / Total Assets 5.25b)
Interest Expense / Debt = 1.50% (Interest Expense 51.8m / Debt 3.46b)
Taxrate = 19.91% (57.1m / 286.8m)
NOPAT = 274.9m (EBIT 343.3m * (1 - 19.91%))
Current Ratio = 2.12 (Total Current Assets 2.02b / Total Current Liabilities 951.5m)
Debt / Equity = 1.99 (Debt 3.46b / totalStockholderEquity, last quarter 1.73b)
Debt / EBITDA = 5.64 (Net Debt 2.85b / EBITDA 505.8m)
Debt / FCF = 13.34 (Net Debt 2.85b / FCF TTM 213.8m)
Total Stockholder Equity = 1.48b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.64% (Net Income 134.3m / Total Assets 5.25b)
RoE = 9.08% (Net Income TTM 134.3m / Total Stockholder Equity 1.48b)
RoCE = 13.45% (EBIT 343.3m / Capital Employed (Equity 1.48b + L.T.Debt 1.07b))
RoIC = 6.84% (NOPAT 274.9m / Invested Capital 4.02b)
WACC = 3.58% (E(1.54b)/V(5.00b) * Re(8.93%) + D(3.46b)/V(5.00b) * Rd(1.50%) * (1-Tc(0.20)))
Discount Rate = 8.93% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -2.22 | Cagr: -0.11%
[DCF] Terminal Value 77.97% ; FCFF base≈175.6m ; Y1≈201.3m ; Y5≈296.3m
[DCF] Fair Price = 11.21 (EV 4.46b - Net Debt 2.85b = Equity 1.61b / Shares 143.4m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.70 | # QB: 0
Revenue Correlation: 98.95 | Revenue CAGR: 8.13% | SUE: 0.36 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.23 | Chg30d=-11.65% | Revisions=-50% | Analysts=4
EPS next Quarter (2026-09-30): EPS=0.26 | Chg30d=+4.00% | Revisions=-17% | Analysts=4
EPS current Year (2026-12-31): EPS=1.25 | Chg30d=-2.84% | Revisions=+50% | GrowthEPS=-18.8% | GrowthRev=+3.3%
EPS next Year (2027-12-31): EPS=1.31 | Chg30d=-0.57% | Revisions=+50% | GrowthEPS=+4.7% | GrowthRev=+4.6%
[Analyst] Revisions Ratio: +13% (up=7, down=5)